foxo4-dri peptide senescent cells inhibitors targeting FOXO4-p53 interactions and inducing cancer cell-specific apoptosis FOXO4-DRI

Oct 18: The gene therapy space celebrated another first on Wednesday, as the FDA cleared the way for the first-ever investigational in vivo CRISPR-based gene editing therapy to enter late-stage development

BPC157 in Gastrointestinal Mucosal and Systemic Cytoprotection Models A foundational body of research [10] has characterized BPC157s cytoprotective activity across a range of gastrointestinal and systemic injury models

doi:10.1002/rem.21498

Provides gastroprotective effects against damage from NSAIDs and other medications that commonly irritate the digestive tract, supporting safe long-term pharmaceutical use when medically necessary

For injectable administration, food timing does not affect absorption